Targeted anti-vascular therapies for ovarian cancer: current evidence

Hall, M., Gourley, C., Mcneish, I. , Ledermann, J., Gore, M., Jayson, G., Perren, T., Rustin, G. and Kaye, S. (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer, 108(2), pp. 250-258. (doi: 10.1038/bjc.2012.541)

[img]
Preview
Text
76031.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.

481kB

Abstract

Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer-angiogenesis.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mcneish, Professor Iain
Authors: Hall, M., Gourley, C., Mcneish, I., Ledermann, J., Gore, M., Jayson, G., Perren, T., Rustin, G., and Kaye, S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:British Journal of Cancer
Publisher:Nature Publishing Group
ISSN:0007-0920
ISSN (Online):1532-1827
Published Online:05 February 2013
Copyright Holders:Copyright © 2013 Cancer Research UK
First Published:First published in British Journal of Cancer 108(2):250-258
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record